Home Visit
Upload
JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR
JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR
51+ booked in last 3 days
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 1 Week
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
JAK2 Mutation Test Overview
The JAK2 mutation test is a specialised genetic test that detects specific mutations in the JAK2 gene, particularly the V617F mutation and other mutations in exons 12-15. This test plays a crucial role in diagnosing and differentiating between various myeloproliferative neoplasms (MPNs), a group of blood disorders characterised by the overproduction of blood cells. By utilising polymerase chain reaction (PCR) and sometimes restriction enzyme-based assays, the test accurately identifies these mutations, providing valuable insights into an individual's health.
The JAK2 gene mutation test is an essential diagnostic tool for healthcare professionals in evaluating patients with suspected MPNs. It helps distinguish between reactive cytosis and chronic myeloproliferative disorders, aiding in the initial evaluation and definitive diagnosis of these conditions.
The JAK-2 (Janus kinase 2) mutation, specifically the V617F variant, detected by Real-Time PCR, is notably associated with myeloproliferative disorders, collectively known as chronic myeloproliferative disorders (CMPD). This genetic mutation plays a pivotal role in the dysregulation of hematopoietic stem cell proliferation, leading to the overproduction of blood cells. Real-Time PCR, a highly sensitive molecular diagnostic technique, enables the detection of the JAK-2 V617F mutation in a patient's genomic DNA, aiding in the diagnosis and classification of CMPDs such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Identifying the JAK-2 mutation by Real-Time PCR holds significant clinical relevance, helping clinicians tailor treatment strategies and monitor disease progression, ultimately improving the management of patients with these hematological disorders.
Reasons for Undergoing the JAK2 Mutation Test
There are several important reasons why a healthcare professional may recommend a JAK2 test:
- To diagnose myeloproliferative neoplasms (MPNs): These include conditions like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
- To differentiate between reactive cytosis and chronic myeloproliferative disorders: This distinction is critical for appropriate treatment.
- To assist in the initial evaluation of suspected MPNs: Helps identify potential underlying conditions.
- To correlate clinical and laboratory findings: Provides a definitive diagnosis by aligning test results with symptoms and other medical data.
- To guide targeted therapy: Ensures precise and effective treatment options.
List of Parameters Considered During the JAK2 Mutation Test
The JAK2 mutation test specifically measures the presence or absence of mutations in the JAK2 gene:
- V617F Mutation: This is the most common mutation, found in approximately 95% of PV cases, 50-60% of ET cases, and 50% of PMF cases. Its presence indicates a high likelihood of an MPN.
- Exons 12-15 Mutations: Although less common, these mutations can also be indicative of MPNs, especially polycythemia vera. They are typically evaluated if the V617F mutation is not detected.
JAK2 Mutation Test Preparation
Preparing for the JAK2 mutation test is straightforward:
- You do not need to fast before the test.
- A 3-10 mL blood sample is typically required, which can be collected in an EDTA or ACD tube. The sample is usually taken through a venipuncture.
JAK2 Mutation Test Results & Interpretation
The results of the JAK2 mutation test can be categorised as either positive or negative, and their interpretation is crucial for guiding further diagnosis and treatment:
- Positive Result: Indicates the presence of a JAK2 mutation, strongly suggestive of a myeloproliferative neoplasm (MPN) such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis. However, a positive result alone is not definitive; clinical symptoms and other laboratory findings must be correlated to confirm the diagnosis. The result specifies the mutation at the nucleotide and protein levels, aiding in understanding the underlying genetic abnormality.
- Negative Result: Suggests no detectable JAK2 mutation, but this does not completely rule out the possibility of an MPN or other related neoplasms. If clinical suspicion remains high, additional tests, such as other genetic mutations or bone marrow examination, may be necessary to reach a conclusive diagnosis.
Home Collection for JAK2 Mutation Test
Metropolis Healthcare offers a convenient home collection service for the JAK2 mutation test, ensuring comfort and safety for patients. A trained phlebotomist will visit your home to collect the blood sample, maintaining the highest standards of sample handling and testing accuracy. With timely and reliable results, you can take proactive steps in managing your health without compromising on quality. Metropolis Healthcare's commitment to accessible healthcare underscores its dedication to providing diagnostic solutions conveniently at your doorstep.
JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR with a clear pricing structure.
The JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR Price in Mumbai is ₹ 7,300 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the presence of a specific genetic mutation in the JAK-2 gene called V617F. This mutation is commonly associated with Polycythemia vera, Myelofibrosis, and Essential thrombocythemia. Detecting this mutation helps diagnose and monitor these blood disorders.
This test is done for the following reasons:
- To diagnose and monitor Polycythemia vera, Myelofibrosis, and Essential thrombocythemia
- To evaluate the effectiveness of treatment for these blood disorders
- To identify individuals at risk for developing these conditions
- To aid in making treatment decisions based on the presence or absence of the JAK-2 V617F mutation
Your doctor may recommend this test if you have:
- Symptoms suggestive of Polycythemia vera, Myelofibrosis, or Essential thrombocythemia
- Abnormal complete blood count results that indicate a possible blood disorder
- A family history of these blood disorders
- A previous diagnosis of these conditions and need to monitor treatment effectiveness
The normal range for this test is the absence of the JAK-2 V617F mutation. If the mutation is detected, it suggests the presence of Polycythemia vera, Myelofibrosis, or Essential thrombocythemia. Abnormal results require further evaluation and discussion with your doctor to determine the best course of action.
During this test:
- A small sample of your blood will be collected using a needle
- The blood sample will be sent to a laboratory for analysis
- Real-Time PCR technique will be used to detect the presence or absence of the JAK-2 V617F mutation
To prepare for this test:
- No special preparations are usually required
- You can eat and drink normally before the test
- Reach out to your healthcare provider about any specific requirements and medications you are taking as they may affect the test results
Other tests that may be ordered alongside the JAK-2 Mutation (CMPD) RT PCR test include:
- Complete Blood Count (CBC): Measures the levels of different blood cells and helps in diagnosing blood disorders
- Bone Marrow Biopsy: Provides detailed information about the bone marrow, aiding in the diagnosis and monitoring of blood disorders
- JAK-2 V617F mutation test
- JAK2 mutation analysis
Polycythemia vera, Myelofibrosis, and Essential thrombocythemia are three blood disorders characterised by abnormal production and function of blood cells. These conditions can lead to complications such as blood clots, bleeding, and an enlarged spleen.
The JAK2 mutation test is a genetic test that detects specific mutations in the JAK2 gene, particularly the V617F mutation and other mutations in exons 12-15. It helps diagnose and differentiate between various myeloproliferative neoplasms (MPNs), a group of blood disorders characterised by the overproduction of blood cells.
Yes, home sample collection is available for the JAK2 gene mutation test. Some labs, such as Metropolis Healthcare, offer free sample collection at home for online bookings, making it convenient for patients to undergo the test without visiting a diagnostic centre.
There are no "normal levels" for the JAK2 test. The test is qualitative, indicating the presence or absence of the mutation. The results are reported as either positive (mutation detected) or negative (mutation not detected).
Yes, a JAK2 mutation test might need to be repeated in several scenarios. If the initial test is negative but clinical suspicion of an MPN remains high, further evaluation, including alternative mutation tests, may be necessary. In cases where the mutation status changes over time, repeat testing might be indicated. For monitoring purposes, although this is less common since the mutation status typically remains stable once identified, a repeat test may be considered.
If there are discrepancies in previous test results or if new symptoms arise that suggest an MPN, retesting can help clarify the diagnosis. Ultimately, the decision to repeat the test should be based on the patient's clinical presentation and the physician's judgment.
A positive JAK2 test indicates the presence of a JAK2 mutation, which is highly suggestive of a myeloproliferative neoplasm. However, a definitive diagnosis requires correlation with clinical and other laboratory features. A positive result does not specify the particular type of MPN, so further diagnostic workup is necessary.
The JAK2 mutation test is used to diagnose and differentiate between various myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. It aids in distinguishing between reactive cytosis and chronic myeloproliferative disorders.
The frequency of testing depends on clinical indications. Generally, the JAK2 gene mutation test is performed once when there is a suspicion of an MPN. Repeat testing is not routine unless there are specific clinical reasons or discrepancies in previous results.
Diseases associated with a positive JAK2 mutation test include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These conditions are characterised by the overproduction of blood cells.
There is no specific timing requirement for the JAK2 test.
No, fasting is not required for the JAK2 mutation test.
No specific precautions are required before the JAK2 gene mutation test.
The JAK2 mutation test primarily detects the presence or absence of specific mutations in the JAK2 gene, particularly the V617F mutation and other mutations in exons 12-15. These mutations are indicative of myeloproliferative neoplasms.
The JAK2 test should be done when there is a clinical suspicion of a myeloproliferative neoplasm (MPN) based on symptoms, physical examination, and other laboratory findings. Your doctor will recommend the test if they suspect you may have an MPN.
The JAK2 mutation test itself is a relatively quick procedure. The blood sample collection typically takes only a few minutes.
The turnaround time for JAK2 mutation test reports varies from lab to lab. In most cases, you can expect to receive the results within a week the sample based on day/time the sample was collected and processed.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp